Get the Stockscreener App
7.96
1.24%
-0.10
After Hours:
8.18
0.22
+2.76%
Cybin Inc stock is traded at $7.96, with a volume of 191.47K.
It is down -1.24% in the last 24 hours and up +18.45% over the past month.
Cybin Inc., a biotechnology company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Cybin U.S., and Natures Journey. The Serenity Life and Cybin U.S. segment engages in the research and development of psychedelic pharmaceutical products. The Natures Journey segment focuses on non-psychedelic medicinal mushroom nutraceutical products. It develops CYB001, a drug candidate that is in phase IIa/b for major depressive disorder; CYB003, a deuterated tryptamine preclinical program to treat alcohol use disorder; CYB004, a deuterated tryptamine preclinical program for therapy resistant psychiatric disorder; and CYB005, a phenethylamine preclinical program for psychiatry and neurology. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.
See More
Previous Close:
$8.06
Open:
$8
24h Volume:
191.47K
Relative Volume:
0.74
Market Cap:
$167.40M
Revenue:
-
Net Income/Loss:
$-52.07M
P/E Ratio:
-38.32
EPS:
-0.2077
Net Cash Flow:
$-44.93M
1W Performance:
+6.56%
1M Performance:
+18.45%
6M Performance:
-23.31%
1Y Performance:
-40.08%
1-Day Range:
$7.71
$8.03
1-Week Range:
$7.42
$8.50
52-Week Range:
$4.81
$13.88
Cybin Inc Stock (CYBN) Company Profile
Name
Cybin Inc
Sector
Industry
Phone
908 764 8385
Address
100 King Street West, Suite 5600, Toronto
Compare CYBN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
7.96 | 152.65M | 0 | -52.07M | -44.93M | -0.2077 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Nov-19-21 | Downgrade | Maxim Group | Buy → Hold |
Cybin Inc Stock (CYBN) Latest News
Cybin taps Thermo Fisher for U.S. manufacturing of CYB003 - MSN
Transcript : Cybin Inc.Special Call - marketscreener.com
(CYBN) Proactive Strategies - news.stocktradersdaily.com
Cboe Canada Single Security - Cboe Global Markets
Cybin CEO to Discuss Strategic Advances at Upcoming Fireside Chat - TipRanks
Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025 - BioSpace
Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025 | CYBN Stock News - GuruFocus
Cybin CEO Reveals Latest on Phase 3 Psychedelics Program and FDA Developments in Exclusive Analyst Chat - Stock Titan
Cybin Engages Thermo Fisher Scientific To Provide U.S.-Based Manufacturing for Its CYB003 Program - Technology Networks
Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Acce - GuruFocus
Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics | CYBN Stock News - GuruFocus
Cybin Applauds FDA Commissioner Dr. Martin Makary’s Call to Accelerate and Prioritize Research on Psychedelic Therapeutics - Yahoo Finance
(CYBN) Investment Analysis - news.stocktradersdaily.com
Cybin, Inc: Covering All Bases as Commercialization Preparations Continue - smartkarma.com
Cybin partners with Thermo Fisher for Phase 3 drug production By Investing.com - Investing.com Nigeria
Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Man - GuruFocus
Thermo Fisher Scientific (NYSE:TMO) Partners With Cybin For Phase 3 Depression Treatment - simplywall.st
Cybin (CYBN) Collaborates with Thermo Fisher for Phase 3 Development | CYBN Stock News - GuruFocus
CYBN Gains on Thermo Fisher Partnership for CYB003 Production - GuruFocus
AGC Bio secures lentiviral contract; Thermo Fisher to make Cybin asset - Endpoints News
Cybin taps Thermo Fisher for U.S. manufacturing of CYB003 (CYBN:NYSE) - Seeking Alpha
Cybin Says Thermo Fisher Scientific to Offer US-Based Manufacturing for Its Depressive Disorder Program - marketscreener.com
Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder | CYBN Stock News - GuruFocus
Cybin partners with Thermo Fisher for Phase 3 drug production - Investing.com
Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder - Business Wire
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase - BioSpace
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase | CYBN Stock News - GuruFocus
Cybin CEO to Speak at Healthcare Showcase, Highlighting Innovations in Mental Health Treatment - TipRanks
Cybin (OTCMKTS:CYBN) Shares Down 0.5% – Time to Sell? - Defense World
Cybin stock price target cut to $150 at H.C. Wainwright - MSN
Cybin secures new patent for depression treatment drug - Investing.com
Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder - BioSpace
Cybin (CYBN) Secures U.S. Patent for CYB003 Program | CYBN Stock News - GuruFocus
Cybin secures new patent for depression treatment drug By Investing.com - Investing.com Nigeria
Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder | CYBN Stock News - GuruFocus
Cybin Announces Additional U.S. Patent Supporting Its CYB003 Breakthrough Therapy Program In Phase 3 Development For Major Depressive Disorder - marketscreener.com
Trading (CYBN) With Integrated Risk Controls - news.stocktradersdaily.com
Cybin wins new Buy from Guggenheim: potential to challenge J&J’s Spravato cited - MSN
Marshall Wace LLP Makes New Investment in Cybin Inc. (NYSE:CYBN) - Defense World
Should You Buy, Sell, or Hold AppLovin Stock Before Q1 Earnings? - The Globe and Mail
Psychedelic drug developer Cybin partners with Osmind - MSN
Cybin (CYBN) Gets a Buy from H.C. Wainwright - The Globe and Mail
Cybin to Participate at the 28th Annual Milken Institute Global Conference | CYBN Stock News - GuruFocus
Cybin Inc Stock (CYBN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Cap:
|
Volume (24h):